Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course

Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. Wi...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jiří Beran, Marián Špajdel, Jiří Slíva
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2021-11-01
Sarja:	Viruses
Aiheet:	inosine pranobex methisoprinol isoprinosine COVID-19 SARS-CoV-2 lymphopenia
Linkit:	https://www.mdpi.com/1999-4915/13/11/2246
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!